Ensartinib before surgery for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests the drug ensartinib to shrink lung cancer before surgery. It is for people with ALK-positive lung cancer that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your lung cancer is a type called adenocarcinoma and is ALK-positive (a specific gene change).
- Your cancer is stage 2 or 3 and can be removed with surgery.
- You have not had previous cancer treatment.
- You are in good general health, with no serious heart, lung, or other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial compares two treatments after lung cancer surgery: a new targeted drug (ensartinib) versus standard chemotherapy. The goal is to see if the targeted drug helps prevent the cancer from coming back.
This trial provides access to ensartinib, an oral medication that targets a specific genetic change in non-small cell lung cancer (NSCLC). It is for people who cannot join other clinical trials for ensartinib and may help control the cancer.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
This trial tests a pill called ensartinib, given before surgery to people with ALK-positive lung cancer. The goal is to see if it helps shrink the tumor and improve the chance of successful surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.